Source disclosure: February 24, 2026
AnGes,Inc. [4563.T]
TOKYO, Feb 24 (Pulse News Wire) – AnGes,Inc. (4563.T) decided to reallocate funds raised through its 46th tranche of subscription rights issuance to repay bonds instead of initial purposes.
The company plans to issue up to ¥2.738 billion more unsecured private placement bonds totaling up to ¥2.74 billion, accelerating repayment schedules. As a result, funds previously allocated for chronic arterial occlusion gene therapy research and development will now be used to expedite manufacturing processes for multiple batches needed for BLA application, aiming for regulatory review initiation in 2026. Additionally, changes were made to funding allocations for expanding newborn screening services via ACRL, relocating Emendo's U.S.
Research facilities, and general operational expenses. Current expenditures stand at ¥387 million for gene therapy, ¥0 for ACRL expansion, ¥0 for Emendo relocation, and ¥3 million for miscellaneous R&D costs. Going forward, AnGes expects minimal impact on consolidated performance due to these adjustments and commits to disclosing any significant developments promptly.
AI-translated content. 🟢 Confidence: High See terms • Original filing